Abstract _ Full Text (HTML) _ Full Text (PDF)

Research Article

Cancer Research Frontiers. 2015 Sep; 1(3): 253-261. doi: 10.17980/2015.253.

Clinical and pathologic predictors of survival in patients with endometrial stromal sarcoma

 

Lesly Dossett MD MPH1, Samir Dalia MD1, Damon Reed MD,1 Kate Fisher MA2, Ji-Hyun Lee PhD2, Robert M. Wenham MD3, Sachin Apte MD3, Ricardo J. Gonzalez MD1[*]

1 Sarcoma Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

2 Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

3 Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL

 

*Corresponding author: Ricardo J. Gonzalez, MD, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612. Email: ricardo.gonzalez@moffitt.org

Citation: Lesly Dossett, et al. Clinical and pathologic predictors of survival in patients with endometrial stromal sarcoma. Cancer Research Frontiers. 2015 Sep; 1(3): 253-261. doi: 10.17980/2015.253.

Copyright: @ 2015 Lesly Dossett, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Competing Interests: The authors declare that they have no competing interests.

Received July 28, 2015; Revised September 22, 2015; Accepted October 2, 2015.

 

ABSTRACT

Endometrial stromal sarcoma (ESS) is a rare uterine neoplasm and the clinical and pathologic factors that predict outcomes are poorly understood. We conducted an institutional retrospective review of patients with the diagnosis of ESS between January 1990 and April 2012. Demographic and clinical features, treatment data and outcomes were collected. Overall survival (OS) and progression free survival (PFS) were estimated using the Kaplan-Meier method. In 37 patients with ESS, 3 clinicopathologic factors were associated with OS in a multivariate model—age (hazard ratio (HR) 1.05, 95% confidence interval (CI) 1.01-1.09, p=0.03), FIGO stage IV versus stage I disease (HR 4.05, 95% CI 1.11-14.8, p=0.03), and estrogen receptor status (HR 0.11, 0.02-0.69, p=0.02). Although the relationship between adjuvant therapy and OS was not significant, we demonstrate an association between adjuvant therapy and improved PFS in patients with ESS. Our observations suggest that advanced age and clinical stage are associated with worse OS and PFS in patients with ESS, while ER expression may be a marker of improved survival.

Keywords: sarcoma, endometrial sarcoma, gynecologic malignancy, outcomes, estrogen receptor

 

 

 

 

 

 

 

 

 

 

 

 

 

Multiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier SchönmannMultiselect Ultimate Query Plugin by InoPlugs Web Design Vienna | Webdesign Wien and Juwelier Schönmann